6533b7d2fe1ef96bd125eb50
RESEARCH PRODUCT
Natural and adoptive T-cell immunity against herpes family viruses after allogeneic hematopoietic stem cell transplantation.
Simone ThomasWolfgang Herrsubject
Adoptive cell transfervirusesmedicine.medical_treatmentT-LymphocytesImmunologyHematopoietic stem cell transplantationBiologyAdaptive Immunitymedicine.disease_causeVirusImmunitymedicineImmunology and AllergyAnimalsHumansVaricella zoster virusHematopoietic Stem Cell TransplantationHerpesviridae InfectionsVirologyEpstein–Barr virusImmunity InnateTransplantationOncologyImmunologyImmunizationViral loaddescription
Reactivated infections with herpes family-related cytomegalovirus, Epstein–Barr virus and varicella zoster virus are serious and sometimes life-threatening complications for patients undergoing allogeneic hematopoietic stem cell transplantation. The pathogenesis of these infections critically involves the slow and inefficient recovery of antiviral T-cell immunity after transplantation. Although efficient drugs to decrease viral load during this vulnerable period have been developed, long-term control of herpes viruses and protection from associated diseases require the sufficient reconstitution of virus-specific memory T cells. To heal the deficiency by immunotherapeutic means, numerous research groups have developed antiviral vaccines and strategies based on the adoptive transfer of virus-specific T cells. This article summarizes the substantial progress made in this field during the past two decades and gives future perspectives about challenges that need to be addressed before antigen-specific immunotherapy against herpes family viruses can be implemented in general clinical practice.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2011-06-15 | Immunotherapy |